Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Novo Nordisk A/S (NYSE:NVO) is one of the best pharma stocks to invest in. Argus analyst Jasper Hellweg downgraded Novo ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

(RTTNews) - Novo Nordisk (NVO) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to update the Ozempic ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

The pharmaceutical giant Novo Nordisk is navigating a complex week, confronting issues in two major markets that highlight ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

Novo Nordisk experienced a turbulent trading session on Monday, with shares plummeting 5.6% by mid-afternoon as investors reacted negatively to a combination of partnership troubles and clinical trial ...

At ELRIG 2025 Dr Barak Gilboa of Novo Nordisk unveiled a suite of AI-enabled approaches that turn brightfield microscopy from ...